Markets:

Overview

News

Currencies

International

Treasuries

Immutep Limited - American Depositary Shares (NQ:IMMP)

2.030 +0.140 (+7.41%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Immutep Limited - American Depositary Shares

< Previous 1 2 3 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 21, 2025

Via Benzinga

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo ↗

May 15, 2025

Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels.

Via Benzinga

Unusual volume stocks in Wednesday's session ↗

May 07, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.

Via Chartmill

Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting ↗

May 24, 2023

Via Benzinga

Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know ↗

May 18, 2023

Via Benzinga

In today's session, these stocks are experiencing unusual volume. ↗

May 06, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 05, 2025

Via Benzinga

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial ↗

November 14, 2024

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.

Via Benzinga

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September ↗

September 16, 2024

Via Benzinga

Topics Stocks

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 29, 2024

Via Benzinga

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 12, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 12, 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Via InvestorPlace

Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars ↗

July 12, 2024

Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer...

Via Benzinga

Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

July 12, 2024

Via Benzinga

Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 27, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

June 27, 2024

Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 24, 2024

Via Benzinga

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday? ↗

April 24, 2024

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 24, 2024

Via Benzinga

Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why ↗

March 05, 2024

Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall...

Via Benzinga

7 Stocks That Could Triple Your Money by 2024 ↗

August 09, 2023

If you want to get well ahead of the market and don’t mind the risk factor, check out these stocks to triple your money.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023 ↗

August 03, 2023

Via Benzinga

3 Best Penny Stocks Under $3 to Buy in June ↗

June 14, 2023

If you don’t mind the immense risks associated with high-potential opportunities, these best penny stocks under $3 could be for you.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 17, 2023

Via Benzinga

Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial ↗

May 17, 2023

Immutep Limited's (NASDAQ: IMMP) lead candidate — a soluble LAG-3 protein, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) —

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 17, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

May 17, 2023

We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning!

Via InvestorPlace

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.